## Arash Nabbi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3925746/publications.pdf Version: 2024-02-01



Adach Narri

#	Article	IF	CITATIONS
1	Loss of Ing3 Expression Results in Growth Retardation and Embryonic Death. Cancers, 2020, 12, 80.	3.7	13
2	Biological Functions of the ING Proteins. Cancers, 2019, 11, 1817.	3.7	29
3	Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein. British Journal of Cancer, 2018, 118, 713-726.	6.4	28
4	Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12. Oncogene, 2018, 37, 4679-4691.	5.9	31
5	ING3 promotes prostate cancer growth by activating the androgen receptor. BMC Medicine, 2017, 15, 103.	5.5	27
6	ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients. Tumor Biology, 2016, 37, 9731-9738.	1.8	14
7	Stromal ING1 expression induces a secretory phenotype and correlates with breast cancer patient survival. Molecular Cancer, 2015, 14, 164.	19.2	7
8	Rapid Isolation of Nuclei from Cells In Vitro. Cold Spring Harbor Protocols, 2015, 2015, pdb.prot083733.	0.3	85
9	Isolation of Pure Nuclei Using a Sucrose Method. Cold Spring Harbor Protocols, 2015, 2015, pdb.prot083741.	0.3	14
10	Isolation of Nuclei. Cold Spring Harbor Protocols, 2015, 2015, pdb.top074583.	0.3	10
11	ING3 protein expression profiling in normal human tissues suggest its role in cellular growth and self-renewal. European Journal of Cell Biology, 2015, 94, 214-222.	3.6	15
12	Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer. Oncotarget, 2015, 6, 37724-37736.	1.8	14
13	RegulatING chromatin regulators: post-translational modification of the ING family of epigenetic regulators. Biochemical Journal, 2013, 450, 433-442.	3.7	13
14	Demethylating Agents as Epigenetic Anticancer Therapeutics. Current Cancer Therapy Reviews, 2013, 9, 24-33.	0.3	0